Stay updated on Dolatav Clinical Trial: Nucleoside Sparing in HIV-1
Sign up to get notified when there's something new on the Dolatav Clinical Trial: Nucleoside Sparing in HIV-1 page.

Latest updates to the Dolatav Clinical Trial: Nucleoside Sparing in HIV-1 page
- Check6 days agoNo Change Detected
- Check14 days agoChange DetectedContent appears unchanged aside from formatting and layout adjustments. No new or removed study data, eligibility criteria, or outcomes are observed.SummaryDifference0.1%

- Check21 days agoChange DetectedRevision banner updated to v3.5.0, replacing v3.4.3. No changes to the study data or page structure are indicated.SummaryDifference0.1%

- Check28 days agoChange DetectedRevision: v3.4.3 updated in the page footer (replacing v3.4.2).SummaryDifference0.1%

- Check57 days agoChange DetectedSite update to Revision: v3.4.2; the previous funding notice and Revision: v3.4.1 have been removed.SummaryDifference0.5%

- Check64 days agoChange DetectedA site-wide notice about government funding lapse and NIH operating status was added, and the revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check71 days agoChange DetectedAdded a 'Show glossary' option and new metadata fields including 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and the revision label 'v3.4.0'. Removed the older entries 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and the previous revision label 'v3.3.4'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Dolatav Clinical Trial: Nucleoside Sparing in HIV-1
Enter your email address, and we'll notify you when there's something new on the Dolatav Clinical Trial: Nucleoside Sparing in HIV-1 page.